# Hemanext

> Hemanext is a Lexington, Massachusetts medical technology company that reengineers how donated red blood cells are stored. Its flagship system, Hemanext ONE, removes oxygen and carbon dioxide from red blood cell units during processing and keeps the environment hypoxic through 42 days of refrigerated storage, slowing the oxidative degradation known as the storage lesion. The system carries FDA marketing authorization (originally via the De Novo pathway) and a CE mark, and aims to deliver a higher-quality blood product for patients who depend on transfusion, including those with thalassemia, sickle cell disease, and trauma.

- **Founded:** 2008
- **Headquarters:** Lexington, Massachusetts, United States
- **Founders:** Martin Cannon (Founder (retired 2023))
- **Team size:** ~36 employees
- **Products:** Hemanext ONE
- **Notable:** First FDA-authorized red blood cell processing and storage system designed to limit oxygen in the storage environment (De Novo authorization)., Subsequent FDA 510(k) clearance for expanded indications, enabling processing of additional RBC types (whole-blood and apheresis-derived AS-3 leukocyte-reduced RBCs)., First blood processing and storage system to receive the AABB Standards-Compliant seal.

## Products & services

- **Hemanext ONE** — An oxygen-controlled red blood cell processing and storage system that removes oxygen and carbon dioxide from RBC units during processing and maintains a hypoxic environment through day 42 of refrigerated storage, preserving membrane integrity, deformability, and metabolic stability. FDA-authorized (De Novo, with subsequent 510(k) clearances for expanded indications) and CE marked.

## Achievements

- First FDA-authorized red blood cell processing and storage system designed to limit oxygen in the storage environment (De Novo authorization).
- Subsequent FDA 510(k) clearance for expanded indications, enabling processing of additional RBC types (whole-blood and apheresis-derived AS-3 leukocyte-reduced RBCs).
- First blood processing and storage system to receive the AABB Standards-Compliant seal.
- CE mark in Europe with multicenter validation across four countries.
- Raised over $119M (reported totals exceeding $100M+, inclusive of NIH grant funding).
- Launched the αO2-PRBCThal clinical trial evaluating Hemanext ONE in transfusion-dependent thalassemia.

## Latest updates

- **2026-03** — Hemanext ONE received FDA 510(k) clearance for expanded indications, broadening the range of RBC products that can be processed in the US.
- **2025-07** — Closed a Series B equity financing round (Series B-3, approx $18.9M reported) at a roughly $172M post-money valuation.
- **2025** — αO2-PRBCThal clinical trial in transfusion-dependent thalassemia progressing, with enrollment targeted for completion.
- **2023-09** — Founder Martin Cannon retired; Andrew Dunham (former CTO) appointed CEO.

## Links

- Website: https://hemanext.com
- LinkedIn: https://www.linkedin.com/company/hemanext
- Twitter/X: https://twitter.com/Hemanext_Inc
- Instagram: https://www.instagram.com/hemanext_official/
- Facebook: https://facebook.com/HemanextOfficial/

---

Profile page: https://yespress.io/hemanext
Published by YesPress — https://yespress.io
Last updated: 2026-06-15